Close-up of a serious female doctor resembling, over 60 with gray hair and glasses, wearing a white lab coat, looking directly at the camera. A large FDA 'Approved' logo is visible on the wall behind her, with text overlay: 'FDA approves ENHERTU for HR+/HER2-low/ultralow breast cancer,' symbolizing medical innovation and authority in breast cancer treatment.

FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights

FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On January 27, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki—better known as Enhertu—for patients with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer. This approval marks a significant step forward, offering … Continue reading FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights

OncologyTube